957 related articles for article (PubMed ID: 26970305)
1. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress.
Qiang X; Xu L; Zhang M; Zhang P; Wang Y; Wang Y; Zhao Z; Chen H; Liu X; Zhang Y
Biochem Biophys Res Commun; 2016 Apr; 472(4):603-9. PubMed ID: 26970305
[TBL] [Abstract][Full Text] [Related]
2. Demethyleneberberine, a natural mitochondria-targeted antioxidant, inhibits mitochondrial dysfunction, oxidative stress, and steatosis in alcoholic liver disease mouse model.
Zhang P; Qiang X; Zhang M; Ma D; Zhao Z; Zhou C; Liu X; Li R; Chen H; Zhang Y
J Pharmacol Exp Ther; 2015 Jan; 352(1):139-47. PubMed ID: 25362106
[TBL] [Abstract][Full Text] [Related]
3. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
Ideta T; Shirakami Y; Miyazaki T; Kochi T; Sakai H; Moriwaki H; Shimizu M
Int J Mol Sci; 2015 Dec; 16(12):29207-18. PubMed ID: 26670228
[TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
Ding Y; Sun X; Chen Y; Deng Y; Qian K
Eur J Pharmacol; 2015 Aug; 761():405-12. PubMed ID: 25967348
[TBL] [Abstract][Full Text] [Related]
5. Xiaozhi formula attenuates non-alcoholic fatty liver disease by regulating lipid metabolism via activation of AMPK and PPAR pathways.
You L; Wang T; Li W; Zhang J; Zheng C; Zheng Y; Li S; Shang Z; Lin J; Wang F; Qian Y; Zhou Z; Kong X; Gao Y; Sun X
J Ethnopharmacol; 2024 Jul; 329():118165. PubMed ID: 38588984
[TBL] [Abstract][Full Text] [Related]
6. Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1/AMPK signaling.
Liang L; Ye S; Jiang R; Zhou X; Zhou J; Meng S
Int Immunopharmacol; 2022 Mar; 104():108306. PubMed ID: 34999396
[TBL] [Abstract][Full Text] [Related]
7. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
8. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
Afonso MB; Rodrigues PM; Carvalho T; Caridade M; Borralho P; Cortez-Pinto H; Castro RE; Rodrigues CM
Clin Sci (Lond); 2015 Oct; 129(8):721-39. PubMed ID: 26201023
[TBL] [Abstract][Full Text] [Related]
9. Gastrodin Ameliorates Oxidative Stress and Proinflammatory Response in Nonalcoholic Fatty Liver Disease through the AMPK/Nrf2 Pathway.
Qu LL; Yu B; Li Z; Jiang WX; Jiang JD; Kong WJ
Phytother Res; 2016 Mar; 30(3):402-11. PubMed ID: 26634892
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight fucoidan attenuates liver injury via SIRT1/AMPK/PGC1α axis in db/db mice.
Zheng Y; Liu T; Wang Z; Xu Y; Zhang Q; Luo D
Int J Biol Macromol; 2018 Jun; 112():929-936. PubMed ID: 29447962
[TBL] [Abstract][Full Text] [Related]
11. SGL 121 Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism Through AMPK Signaling Pathway.
Kim DE; Chang BY; Jeon BM; Baek JI; Kim SC; Kim SY
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630596
[TBL] [Abstract][Full Text] [Related]
12. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
[TBL] [Abstract][Full Text] [Related]
13. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis.
Lee DH; Han DH; Nam KT; Park JS; Kim SH; Lee M; Kim G; Min BS; Cha BS; Lee YS; Sung SH; Jeong H; Ji HW; Lee MJ; Lee JS; Lee HY; Chun Y; Kim J; Komatsu M; Lee YH; Bae SH
Free Radic Biol Med; 2016 Oct; 99():520-532. PubMed ID: 27634173
[TBL] [Abstract][Full Text] [Related]
14. Isoquercetin Improves Hepatic Lipid Accumulation by Activating AMPK Pathway and Suppressing TGF-β Signaling on an HFD-Induced Nonalcoholic Fatty Liver Disease Rat Model.
Qin G; Ma J; Huang Q; Yin H; Han J; Li M; Deng Y; Wang B; Hassan W; Shang J
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572631
[TBL] [Abstract][Full Text] [Related]
15. Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice.
Lin Q; Huang Z; Cai G; Fan X; Yan X; Liu Z; Zhao Z; Li J; Li J; Shi H; Kong M; Zheng MH; Conklin DJ; Epstein PN; Wintergerst KA; Mohammadi M; Cai L; Li X; Li Y; Tan Y
Hepatology; 2021 Jun; 73(6):2206-2222. PubMed ID: 32965675
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Rb2 Alleviates Hepatic Lipid Accumulation by Restoring Autophagy via Induction of Sirt1 and Activation of AMPK.
Huang Q; Wang T; Yang L; Wang HY
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28534819
[TBL] [Abstract][Full Text] [Related]
17. Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis.
Huang R; Guo F; Li Y; Liang Y; Li G; Fu P; Ma L
Phytomedicine; 2021 Nov; 92():153739. PubMed ID: 34592488
[TBL] [Abstract][Full Text] [Related]
18. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
[TBL] [Abstract][Full Text] [Related]
19. Bouchardatine analogue alleviates non-alcoholic hepatic fatty liver disease/non-alcoholic steatohepatitis in high-fat fed mice by inhibiting ATP synthase activity.
Rao Y; Lu YT; Li C; Song QQ; Xu YH; Xu Z; Hu YT; Yu H; Gao L; Gu LQ; Ye JM; Huang ZS
Br J Pharmacol; 2019 Aug; 176(16):2877-2893. PubMed ID: 31113010
[TBL] [Abstract][Full Text] [Related]
20. Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway.
Yao H; Tao X; Xu L; Qi Y; Yin L; Han X; Xu Y; Zheng L; Peng J
Pharmacol Res; 2018 May; 131():51-60. PubMed ID: 29574225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
